I think that's probably much of the same with "punters" assuming...

I think that's probably much of the same with "punters" assuming it is much further advanced than it is ie. Still in small animals with plans for data next year miles away from human trials and imo still the whole pk/pd conondrum before big pharma partners or potential ones take a big bite. Have to remember it's still a very new tech still with not many peptide drugs breaking the market and still with the company chasing "holy grails" that have eluded many over the past 30 or 40 odd years despite much excitement. It's what PYC has always been though - targeting a market that has evaded the masses but richly rewarding if they come through.